B

Beijing Tiantan Biological Products Corp Ltd
SSE:600161

Watchlist Manager
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Watchlist
Price: 30.07 CNY 6.1% Market Closed
Updated: Jun 3, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

14.2B
-3%
Assets
Growth Rates:
1 Year
+10%
3 Years
+88%
5 Years
+180%
7 Years
+136%
10 Years
+152%
4.4B
-13%
Liabilities
Growth Rates:
1 Year
+6%
3 Years
+44%
5 Years
+157%
7 Years
+19%
10 Years
+18%
9.8B
+2%
Equity
Growth Rates:
1 Year
+12%
3 Years
+117%
5 Years
+191%
7 Years
+319%
10 Years
+410%

Balance Sheet Decomposition
Beijing Tiantan Biological Products Corp Ltd

14.2B
Assets
4.4B
Liabilities
14.2B
Assets
4.4B
Liabilities
Current Assets 7.6B
Cash & Short-Term Investments 2.8B
Receivables 133.2m
Other Current Assets 4.6B
Non-Current Assets 6.6B
Long-Term Investments 214.8m
PP&E 5B
Intangibles 1.2B
Other Non-Current Assets 165.9m
Current Liabilities 1.3B
Accounts Payable 74.4m
Accrued Liabilities 98.1m
Short-Term Debt 119.1m
Other Current Liabilities 988m
Non-Current Liabilities 3.1B
Long-Term Debt 24.4m
Other Non-Current Liabilities 3.1B

Balance Sheet
Beijing Tiantan Biological Products Corp Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
953
564
670
1 919
1 250
1 412
1 748
3 317
2 194
2 833
Cash
1
1
1
4
3
5
6
3 317
2 194
2 833
Cash Equivalents
953
563
668
1 915
1 246
1 407
1 742
0
0
0
Total Receivables
292
230
316
319
450
659
713
1 050
1 201
133
Accounts Receivables
218
150
213
6
6
9
12
10
33
18
Other Receivables
74
80
103
313
444
650
700
1 040
1 168
115
Inventory
814
944
1 031
1 582
1 709
1 950
2 172
2 144
2 332
2 844
Other Current Assets
20
20
27
26
24
26
24
1 035
1 544
1 759
Total Current Assets
2 080
1 758
2 043
3 846
3 433
4 046
4 656
7 546
7 271
7 569
PP&E Net
3 546
3 478
3 453
981
1 121
1 602
2 075
2 872
4 202
5 014
PP&E Gross
3 546
3 478
3 453
981
1 121
1 602
2 075
2 872
4 202
5 014
Accumulated Depreciation
739
849
1 091
878
989
1 064
1 160
1 288
1 545
1 749
Intangible Assets
204
192
212
240
287
331
394
701
930
1 050
Goodwill
0
0
94
94
96
115
115
128
174
174
Long-Term Investments
47
83
80
77
82
133
194
222
218
215
Other Long-Term Assets
138
121
131
22
49
87
107
109
134
166
Other Assets
0
0
94
94
96
115
115
128
174
174
Total Assets
6 015
N/A
5 632
-6%
6 013
+7%
5 260
-13%
5 067
-4%
6 314
+25%
7 541
+19%
11 578
+54%
12 929
+12%
14 188
+10%
Liabilities
Accounts Payable
43
46
57
58
43
44
45
73
69
74
Accrued Liabilities
78
77
85
41
39
40
42
62
99
98
Short-Term Debt
280
413
370
332
31
6
212
11
27
119
Current Portion of Long-Term Debt
1 346
170
162
0
0
0
126
125
124
18
Other Current Liabilities
804
717
565
172
369
562
515
539
838
970
Total Current Liabilities
2 551
1 423
1 238
602
482
652
939
810
1 157
1 280
Long-Term Debt
1 045
1 780
1 912
200
231
401
475
384
279
24
Deferred Income Tax
0
0
3
3
3
10
11
20
31
29
Minority Interest
277
295
280
782
976
1 239
1 513
2 215
2 560
2 932
Other Liabilities
202
193
238
4
4
75
85
97
106
101
Total Liabilities
4 075
N/A
3 690
-9%
3 671
-1%
1 592
-57%
1 696
+7%
2 376
+40%
3 023
+27%
3 526
+17%
4 134
+17%
4 365
+6%
Equity
Common Stock
516
516
516
670
871
1 045
1 254
1 373
1 648
1 648
Retained Earnings
1 264
1 274
1 521
2 116
2 226
2 619
2 989
3 612
4 355
5 382
Additional Paid In Capital
164
164
316
882
275
275
275
3 067
2 793
2 793
Other Equity
3
12
11
0
0
0
0
0
0
0
Total Equity
1 941
N/A
1 942
+0%
2 342
+21%
3 668
+57%
3 371
-8%
3 939
+17%
4 518
+15%
8 052
+78%
8 795
+9%
9 823
+12%
Total Liabilities & Equity
6 015
N/A
5 632
-6%
6 013
+7%
5 260
-13%
5 067
-4%
6 314
+25%
7 541
+19%
11 578
+54%
12 929
+12%
14 188
+10%
Shares Outstanding
Common Shares Outstanding
1 254
1 254
1 255
1 255
1 255
1 254
1 254
1 648
1 648
1 648

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 143,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.